On September 1, 2026 Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, reported its Chairman, President and Chief Executive Officer Mathai Mammen, M.D., Ph.D., will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY at 2:35 PM ET on Wednesday, September 16, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live audio webcast will be available on the Investors section of the Parabilis website at investors.parabilismed.com.

(Press release, Parabilis Medicines, SEP 1, 2026, View Source [SID1234670525])

On September 1, 2026 Tango Therapeutics, Inc. (NASDAQ: TNGX) ("Tango Therapeutics" or the "Company") reported that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live webcast will be available under the "Events & Presentations" tab on the "Investors" page of the Company’s website on the day of the event. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.

(Press release, Tango Therapeutics, SEP 1, 2026, View Source [SID1234670524])

On September 1, 2026 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, reported that management will participate in the following investor conferences in September.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 21st Annual Healthcare Conference
Date: Tuesday, September 8, 2026
Fireside Chat: 2:15 p.m. ET
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Fireside Chat: 10:20 a.m. ET
Location: New York, NY

Morgan Stanley 24th Annual Global Healthcare Conference
Date: Monday, September 14, 2026
Fireside Chat: 1:50 p.m. ET
Location: New York, NY

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

(Press release, CytomX Therapeutics, SEP 1, 2026, View Source [SID1234670523])

On September 1, 2026 Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported it will be participating in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15, 2026, at 1:50 p.m. Pacific Time / 4:50 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.adaptivebiotech.com.

(Press release, Adaptive Biotechnologies, SEP 1, 2026, View Source [SID1234670522])

On September 1, 2026 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, reported that management will participate in the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference (New York, NY) – September 14, 2026

A webcast of the fireside chat will be accessible via the "Events & Presentations" section of Monte Rosa’s website at ir.monterosatx.com, and archived versions will be made available for 30 days following the presentations.

(Press release, Monte Rosa Therapeutics, SEP 1, 2026, View Source [SID1234670521])